ReviewJournal of molecular and cellular cardiology2008
Guided stem cell cardiopoiesis: discovery and translation.
Review in Journal of molecular and cellular cardiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Decoded cardiopoietic cell secretome linkage to heart repair biosignature.Stem cells translational medicine · 2024Article
- Priming mesenchymal stem cells to develop "super stem cells".World journal of stem cells · 2024Article
- Mass Customized Outlook for Regenerative Heart Failure Care.International journal of molecular sciences · 2021Review
- Brachyury engineers cardiac repair competent stem cells.Stem cells translational medicine · 2021Article
- Pathway-specific reporter genes to study stem cell biology.Stem cells (Dayton, Ohio) · 2020Article
- Cardiopoietic stem cell therapy restores infarction-altered cardiac proteome.NPJ Regenerative medicine · 2020Article
- Cardiac fibrosis: potential therapeutic targets.Translational research : the journal of laboratory and clinical medicine · 2019Review
- MTissue engineering. Part A · 2019Article
- A mechanistic roadmap for the clinical application of cardiac cell therapies.Nature biomedical engineering · 2018Article
- Stem cell therapy for heart failure: Ensuring regenerative proficiency.Trends in cardiovascular medicine · 2016Review
- Pericytes: A newly recognized player in wound healing.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2016Review
- "Second-generation" stem cells for cardiac repair.World journal of stem cells · 2015Review
- Pericytes from human veins for treatment of myocardial ischemia.Trends in cardiovascular medicine · 2013Review
- Energy metabolism plasticity enables stemness programs.Annals of the New York Academy of Sciences · 2012Review
- Developmental enhancement of adenylate kinase-AMPK metabolic signaling axis supports stem cell cardiac differentiation.PloS one · 2011Article
- Adult stem cells: from new cell sources to changes in methodology.Journal of cardiovascular translational research · 2011Review
- Protein expression of mesenchymal stem cells after transfection of pcDNA3.1⁻-hVEGF₁₆₅ by ultrasound-targeted microbubble destruction.Journal of biomedicine & biotechnology · 2011Article
- Induced pluripotent stem cells: developmental biology to regenerative medicine.Nature reviews. Cardiology · 2010Review
- Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction.Journal of the American College of Cardiology · 2010Article
- Decoded calreticulin-deficient embryonic stem cell transcriptome resolves latent cardiophenotype.Stem cells (Dayton, Ohio) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Over 1000 patients have participated worldwide in clinical trials exploring the therapeutic value of bone marrow-derived cells in ischemic heart disease. Meta-analysis evaluation of this global effort indicates that adult stem cell therapy is in general safe, but yields a rather modest level of improvement in cardiac function and structural remodeling in the setting of acute myocardial infarction or chronic heart failure. Although promising, the potential of translating adult stem cell-based therapy from bench to bedside has yet to be fully realized. Inter-trial and inter-patient variability contribute to disparity in the regenerative potential of transplanted stem cells with unpredictable efficacy on follow-up. Strategies that mimic the natural embryonic program for uniform recruitment of cardiogenic progenitors from adult sources are currently tested to secure consistent outcome. Guided cardiopoiesis has been implemented with mesenchymal stem cells obtained from bone marrow of healthy volunteers, using a cocktail of secreted proteins that recapitulate components of the endodermal secretome critical for cardiogenic induction of embryonic mesoderm. With appropriate validation of this newly derived cardiopoietic phenotype, the next generation of trials should achieve demonstrable benefit across patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.